Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

This study has been terminated.
Information provided by (Responsible Party):
Kimberly Liu, University of Toronto Identifier:
First received: February 15, 2011
Last updated: October 1, 2012
Last verified: October 2012

February 15, 2011
October 1, 2012
February 2006
March 2010   (final data collection date for primary outcome measure)
Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description) [ Time Frame: patients were followed for the duration of an in-vitro fertilization cycle- 2 months ] [ Designated as safety issue: No ]
abnormal bleeding, intermittent bleeding, headache, breast discomfort, bloating, mood swings, nausea, vaginal discharge, vomitting, weight gain
Side effects [ Designated as safety issue: Yes ]
Side effects of OCP
Complete list of historical versions of study NCT01298128 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment
A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Not Provided
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Infertility
  • In-vitro Fertilization
  • Drug: NuvaRing
    NuvaRIng 21 days for IVF pre-treatment.
  • Drug: marvelon
    marvelon 21 daily
    Other Name: Marvelon
  • Experimental: NuvaRing
    NuvaRing for IVF pre-treatment
    Intervention: Drug: NuvaRing
  • Active Comparator: Combined oral contraceptive pill
    OCP for IVF pre-treatment
    Intervention: Drug: marvelon
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients less than 38 years of age.
  • Healthy women starting their first IVF/ICSI cycle.
  • No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1
  • Consent to randomization.

Exclusion Criteria:

  • Any contraindication to COC use.
  • Hypersensitivity to Nuva ring or any of its components.
  • Language barrier to consent.
18 Years to 38 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
CFRH- 001
Kimberly Liu, University of Toronto
University of Toronto
Not Provided
Principal Investigator: Kimberly E Liu, MD Mount Sinai Hospital, Toronto ON
University of Toronto
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP